Ariel Ernesto Cariaga-Martinez

Dr. Ariel Ernesto Cariaga-Martinez

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in Anti-Cancer Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
PLPilar Lopez-Ruiz
Pilar Lopez-Ruiz
JRJavier Rodriguez-Ubreva
Javier Rodriguez-Ubreva
Ariel Ernesto Cariaga-MartinezAriel Ernesto Cariaga-Martinez
Ariel Ernesto Cariaga-Martinez
MCMaria Alicia Cortes
Maria Alicia Cortes
BCBegona Colas
Begona Colas
The reversible phosphorylation of tyrosine residues in proteins, which is governed by the balanced action of protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs), is a key element of the signaling pathways that are involved in the control of cell proliferation. Deregulation of either of these key regulators leads to abnormal cell signaling, which is largely associated with human pathologies including cancer. This review focuses on recent studies on the role of the protein tyrosine phosphatase SHP-1 on cell-cycle regulation and its possible roles in tumour onset and progression. SHP-1 is a PTP with two SH2 domains that is expressed in haematopoietic cells and, moderately, in many other cell types, especially malignant epithelial cells. SHP-1 regulates cell proliferation, whether it is by controlling mitogenic pathways activated by receptors with tyrosine kinase activity, or by regulating components of the cell-cycle machinery such as CDK2, p27 and cyclin D1. Since several inhibitors targeting SHP-1 have demonstrated their value in cancer treatment, this phosphatase has been proposed as a therapeutic target for this pathology.

15 July 2014 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
AFAbel Suarez Fueyo
Abel Suarez Fueyo
JRJosé Manuel Rojas
José Manuel Rojas
Ariel Ernesto Cariaga-MartinezAriel Ernesto Cariaga-Martinez
Ariel Ernesto Cariaga-Martinez
EGEsther Garcia
Esther Garcia
BSBart H. Steiner
Bart H. Steiner
Ana Clara CarreraAna Clara Carrera
Ana Clara Carrera
Systemic lupus erythematosus (SLE) is a human chronic inflammatory disease generated and maintained throughout life by autoreactive T and B cells. Class I phosphoinositide 3-kinases (PI3K) are heterodimers composed of a regulatory and a catalytic subunit that catalyze phosphoinositide-3,4,5-P3 formation and regulate cell survival, migration, and division. Activity of the PI3Kδ isoform is enhanced in human SLE patient PBLs. In this study, we analyzed the effect of inhibiting PI3Kδ in MRL/lpr mice, a model of human SLE. We found that PI3Kδ inhibition ameliorated lupus progression. Treatment of these mice with a PI3Kδ inhibitor reduced the excessive numbers of CD4+ effector/memory cells and B cells. In addition, this treatment reduced serum TNF-α levels and the number of macrophages infiltrating the kidney. Expression of inactive PI3Kδ, but not deletion of the other hematopoietic isoform PI3Kγ, reduced the ability of macrophages to cross the basement membrane, a process required to infiltrate the kidney, explaining MRL/lpr mice improvement by pharmacologic inhibition of PI3Kδ. The observations that p110δ inhibitor prolonged mouse life span, reduced disease symptoms, and showed no obvious secondary effects indicates that PI3Kδ is a promising target for SLE.

19 October 2009 in Oncogene
Verified
Journal Article
Closed access
FRF J Rodríguez-Ubreva
F J Rodríguez-Ubreva
Ariel Ernesto Cariaga-MartinezAriel Ernesto Cariaga-Martinez
Ariel Ernesto Cariaga-Martinez
MCM A Cortés
M A Cortés
MPM Romero-De Pablos
M Romero-De Pablos
SRS Ropero
S Ropero
BCB Colás
B Colás

1 July 2013 in Cellular Signalling
Verified
Journal Article
Closed access
Ariel Ernesto Cariaga-MartinezAriel Ernesto Cariaga-Martinez
Ariel Ernesto Cariaga-Martinez
PLPilar López-Ruiz
Pilar López-Ruiz
MNM. Paz Nombela-Blanco
M. Paz Nombela-Blanco
OMOmar Motiño
Omar Motiño
AGAna González-Corpas
Ana González-Corpas
BCBegoña Colás
Begoña Colás

11 May 2016 in Frontiers in Neuroscience
Verified
Journal Article
Open access
PDF file
Ariel Ernesto Cariaga-MartinezAriel Ernesto Cariaga-Martinez
Ariel Ernesto Cariaga-Martinez
JSJerónimo Saiz-Ruiz
Jerónimo Saiz-Ruiz
RARaúl Alelú-Paz
Raúl Alelú-Paz
Schizophrenia is a complex psychiatric disorder characterized by the presence of positive, negative and cognitive symptoms that lacks a unifying neuropathology. In the present paper, we will review the current understanding of molecular dysregulation in schizophrenia, including genetic and epigenetic studies. In relation to the latter, basic research suggests that normal cognition is regulated by epigenetic mechanisms and its dysfunction occurs upon epigenetic misregulation, providing new insights into missing heritability of complex psychiatric diseases, referring to the discrepancy between epidemiological heritability and the proportion of phenotypic variation explained by DNA sequence difference. In schizophrenia the absence of consistently replicated genetic effects together with evidence for lasting changes in gene expression after environmental exposures suggest a role of epigenetic mechanisms. In this review we will focus on epigenetic modifications as a key mechanism through which environmental factors interact with individual's genetic constitution to affect risk of psychotic conditions throughout life.

30 September 2016 in Frontiers in Psychology
Verified
Journal Article
Open access
PDF file
RARaúl Alelú-Paz
Raúl Alelú-Paz
FCFrancisco J. Carmona
Francisco J. Carmona
JSJose V. Sanchez-Mut
Jose V. Sanchez-Mut
Ariel Ernesto Cariaga-MartinezAriel Ernesto Cariaga-Martinez
Ariel Ernesto Cariaga-Martinez
AGAna González-Corpas
Ana González-Corpas
SRSantiago Ropero
Santiago Ropero
Attempts to discover genes that are involved in the pathogenesis of major psychiatric disorders have been frustrating and often fruitless. Concern is building about the need to understand the complex ways in which nature and nurture interact to produce mental illness. We analyze the epigenome in several brain regions from schizophrenic patients with severe cognitive impairment using high-resolution (450k) DNA methylation array. We identified 159 differentially methylated CpG sites included in known and novel candidate genes sequences as well as in and intergenic sequences wich functions remain unknown. We found that altered DNA methylation is not restricted to a particular region, but includes others such as CpG shelves and gene bodies, indicating the presence of different DNA methylation signatures depending on the brain area analyzed. Our findings suggest that epimutations are not relatables between different tissues or even between tissues’ regions, highlighting the need to adqueately study brain samples to obtain reliable data concerning the epigenetics of schizophrenia.